
Florence Pasquier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2337453/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2005, 65, 1863-1872.	1.1	4,604
2	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	7.6	3,913
3	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	10.2	3,755
4	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
5	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
6	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	21.4	2,155
7	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
8	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
9	A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. Stroke, 2001, 32, 1318-1322.	2.0	1,506
10	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
11	The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology, 1999, 52, 1158-1158.	1.1	704
12	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
13	Poststroke dementia. Lancet Neurology, The, 2005, 4, 752-759.	10.2	578
14	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry, 2011, 16, 903-907.	7.9	529
15	Diagnostic Criteria for Vascular Cognitive Disorders. Alzheimer Disease and Associated Disorders, 2014, 28, 206-218.	1.3	529
16	Amnestic syndrome of the medial temporal type identifies prodromal AD. Neurology, 2007, 69, 1859-1867.	1.1	425
17	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimer's Research and Therapy, 2015, 7, 17.	6.2	419
18	Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric Infarcts. European Neurology, 1996, 36, 268-272.	1.4	383

#	Article	IF	CITATIONS
19	APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Medicine, 2017, 14, e1002270.	8.4	358
20	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain, 2008, 131, 732-746.	7.6	331
21	Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurology, The, 2012, 11, 851-859.	10.2	331
22	Poststroke dementia. Neurology, 2001, 57, 1216-1222.	1.1	318
23	Origin of Piezoelectricity in an Electrospun Poly(vinylidene fluorideâ€ŧrifluoroethylene) Nanofiber Webâ€Based Nanogenerator and Nanoâ€Pressure Sensor. Macromolecular Rapid Communications, 2011, 32, 831-837.	3.9	316
24	Frontotemporal Dementia: A Randomised, Controlled Trial with Trazodone. Dementia and Geriatric Cognitive Disorders, 2004, 17, 355-359.	1.5	314
25	Drugs With Anticholinergic Properties, Cognitive Decline, and Dementia in an Elderly General Population. Archives of Internal Medicine, 2009, 169, 1317.	3.8	312
26	A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, AÎ ² Levels, and Alzheimer's Disease Risk. Cell, 2008, 133, 1149-1161.	28.9	310
27	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
28	Early diagnosis of dementia: neuropsychology. Journal of Neurology, 1999, 246, 6-15.	3.6	288
29	Mutations of the <i>presenilin I</i> gene in families with early-onset Alzheimer's disease. Human Molecular Genetics, 1995, 4, 2373-2377.	2.9	268
30	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
31	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2018, 14, 280-292.	0.8	246
32	White Matter Changes on CT and MRI: An Overview of Visual Rating Scales. European Neurology, 1998, 39, 80-89.	1.4	244
33	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Review of Proteomics, 2008, 5, 207-224.	3.0	242
34	<scp>EFNSâ€ENS</scp> Guidelines on the diagnosis and management of disorders associated with dementia. European Journal of Neurology, 2012, 19, 1159-1179.	3.3	239
35	Why are stroke patients prone to develop dementia?. Journal of Neurology, 1997, 244, 135-142.	3.6	238
36	Diabetes mellitus and dementia. Diabetes and Metabolism, 2006, 32, 403-414.	2.9	231

#	Article	IF	CITATIONS
37	Phenotype associated with APP duplication in five families. Brain, 2006, 129, 2966-2976.	7.6	230
38	Risk profiles for mild cognitive impairment and progression to dementia are gender specific. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 979-984.	1.9	222
39	Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology, 2009, 73, 674-680.	1.1	214
40	Preexisting Dementia in Stroke Patients. Stroke, 1997, 28, 2429-2436.	2.0	208
41	Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain, 2008, 131, 772-784.	7.6	206
42	Prediction of pathology in primary progressive language and speech disorders. Neurology, 2010, 74, 42-49.	1.1	187
43	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
44	Sleep disorders in aging and dementia. Journal of Nutrition, Health and Aging, 2010, 14, 212-217.	3.3	179
45	Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Molecular Psychiatry, 2012, 17, 223-233.	7.9	179
46	Perception of Emotion in Frontotemporal Dementia and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1999, 13, 96-101.	1.3	178
47	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
48	A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Human Molecular Genetics, 1998, 7, 533-540.	2.9	170
49	Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Molecular Psychiatry, 2009, 14, 1004-1016.	7.9	167
50	Qualitative Assessment of Cerebral Atrophy on MRI: Inter- and Intra-Observer Reproducibility in Dementia and Normal Aging. European Neurology, 1997, 37, 95-99.	1.4	166
51	Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. American Journal of Human Genetics, 2016, 98, 1208-1219.	6.2	164
52	Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology, 2002, 59, 398-407.	1.1	162
53	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020, 143, 1632-1650.	7.6	158
54	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155

#	Article	IF	CITATIONS
55	Implication of the Immune System in Alzheimer's Disease: Evidence from Genome-Wide Pathway Analysis. Journal of Alzheimer's Disease, 2010, 20, 1107-1118.	2.6	152
56	Follow-Up of Patients with History of Cervical Artery Dissection. Cerebrovascular Diseases, 1995, 5, 43-49.	1.7	148
57	Subcortical Hyperintensities Are Associated With Cognitive Decline in Patients With Mild Cognitive Impairment. Stroke, 2007, 38, 2924-2930.	2.0	145
58	Confusional State in Stroke. Stroke, 1999, 30, 773-779.	2.0	143
59	C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain, 2013, 136, 385-391.	7.6	143
60	The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2017, 13, 624-633.	0.8	143
61	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
62	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
63	Verbal fluency in dementia of frontal lobe type and dementia of Alzheimer type Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 81-84.	1.9	131
64	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Medicine, 2018, 15, e1002660.	8.4	131
65	Depressive symptoms after stroke and relationship with dementia. Neurology, 2004, 62, 905-911.	1.1	129
66	Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Human Molecular Genetics, 1998, 7, 1511-1516.	2.9	127
67	Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1405-1408.	1.9	120
68	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiology of Aging, 2017, 59, 220.e1-220.e9.	3.1	116
69	The nature of semantic memory deficits in Alzheimer's disease: New insights from hyperpriming effects. Brain, 2001, 124, 1522-1532.	7.6	114
70	My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer's disease. Brain, 2012, 135, 3026-3038.	7.6	114
71	The French Series of Autosomal Dominant Early Onset Alzheimer's Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2012, 30, 847-856.	2.6	113
72	Frontotemporal Behavioral Scale. Alzheimer Disease and Associated Disorders, 1998, 12, 335-339.	1.3	109

#	Article	IF	CITATIONS
73	Natural history of primary progressive aphasia. Neurology, 2005, 65, 887-891.	1.1	108
74	Early Cognitive, Structural, and Microstructural Changes in Presymptomatic <i>C9orf72</i> Carriers Younger Than 40 Years. JAMA Neurology, 2018, 75, 236.	9.0	108
75	The Clinical Picture of Frontotemporal Dementia: Diagnosis and Follow-Up. Dementia and Geriatric Cognitive Disorders, 1999, 10, 10-14.	1.5	103
76	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Molecular Psychiatry, 2013, 18, 461-470.	7.9	103
77	Contribution of <i>APOE</i> promoter polymorphisms to Alzheimer's disease risk. Neurology, 2002, 59, 59-66.	1.1	102
78	Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1041-1049.	0.8	102
79	Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1624-1629.	1.9	101
80	Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer's Research and Therapy, 2015, 7, 30.	6.2	101
81	Perception of Emotion on Faces in Frontotemporal Dementia and Alzheimer's Disease: A Longitudinal Study. Dementia and Geriatric Cognitive Disorders, 2005, 19, 37-41.	1.5	98
82	The Unique Experience of Spouses in Early-Onset Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 634-641.	1.9	98
83	Joint Effect of White Matter Lesions and Hippocampal Volumes on Severity of Cognitive Decline: The 3C-Dijon MRI Study. Journal of Alzheimer's Disease, 2010, 20, 453-463.	2.6	97
84	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
85	Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. International Psychogeriatrics, 2016, 28, 707-717.	1.0	96
86	SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Molecular Psychiatry, 2016, 21, 831-836.	7.9	96
87	Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2006, 65, 278-288.	1.7	95
88	Poststroke Dementia. Archives of Neurology, 2003, 60, 585.	4.5	94
89	An analysis of communication in conversation in patients with dementia. Neuropsychologia, 2010, 48, 3884-3890.	1.6	94
90	C9ORF72 Repeat Expansions in the Frontotemporal Dementias Spectrum of Diseases: A Flow-chart for Genetic Testing. Journal of Alzheimer's Disease, 2013, 34, 485-499.	2.6	93

#	Article	IF	CITATIONS
91	Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neuroscience Letters, 1997, 227, 68-70.	2.1	92
92	Poststroke Dementia. Cerebrovascular Diseases, 2006, 22, 61-70.	1.7	91
93	Influence of cognitive impairment on the institutionalisation rate 3 years after a stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 56-59.	1.9	91
94	Siderophile and chalcophile elemental constraints on the origin of the Jinchuan Ni-Cu-(PGE) sulfide deposit, NW China. Geochimica Et Cosmochimica Acta, 2009, 73, 404-424.	3.9	91
95	Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to 99mTc HmPAO SPECT data. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 661-663.	1.9	90
96	The dynamic time course of semantic memory impairment in Alzheimer's disease: clues from hyperpriming and hypopriming effects. Brain, 2002, 125, 2044-2057.	7.6	88
97	Tau aggregation in the hippocampal formation: an ageing or a pathological process?. Experimental Gerontology, 2002, 37, 1291-1296.	2.8	88
98	Natural History of Frontotemporal Dementia: Comparison with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2004, 17, 253-257.	1.5	86
99	Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Neuroscience Letters, 2002, 328, 1-4.	2.1	85
100	Tau as a biomarker of neurodegenerative diseases. Biomarkers in Medicine, 2008, 2, 363-384.	1.4	83
101	Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 24-Week Open-Label Study. Dementia and Geriatric Cognitive Disorders, 2007, 23, 401-405.	1.5	82
102	Vascular Subcortical Hyperintensities Predict Conversion to Vascular and Mixed Dementia in MCI Patients. Stroke, 2008, 39, 2046-2051.	2.0	82
103	Seizures in dominantly inherited Alzheimer disease. Neurology, 2016, 87, 912-919.	1.1	81
104	Leukoaraiosis More Than Dementia Is a Predictor of Stroke Recurrence. Stroke, 2003, 34, 2935-2940.	2.0	80
105	Simulation of nonlinear interactions between waves and floating bodies through a finite-element-based numerical tank. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2004, 460, 2797-2817.	2.1	78
106	Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 1131-1143.	2.6	78
107	Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Molecular Neurodegeneration, 2012, 7, 3.	10.8	77
108	Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. European Journal of Human Genetics, 2016, 24, 710-716.	2.8	77

#	Article	IF	CITATIONS
109	The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer's disease. Human Molecular Genetics, 2000, 9, 2275-2280.	2.9	75
110	Comparison of 7.0-T T ₂ *-Magnetic Resonance Imaging of Cerebral Bleeds in Post-Mortem Brain Sections of Alzheimer Patients with Their Neuropathological Correlates. Cerebrovascular Diseases, 2011, 31, 511-517.	1.7	75
111	Influence of prestroke dementia on early and delayed mortality in stroke patients. Journal of Neurology, 2003, 250, 10-16.	3.6	74
112	What are the causes of pre-existing dementia in patients with intracerebral haemorrhages?. Brain, 2010, 133, 3281-3289.	7.6	74
113	Cerebral Hypoperfusion and Hypometabolism Detected by Arterial Spin Labeling MRI and FDGâ€PET in Earlyâ€Onset Alzheimer's Disease. Journal of Neuroimaging, 2016, 26, 207-212.	2.0	73
114	Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 133-139.	1.9	72
115	Prevalence of small cerebral bleeds in patients with a neurodegenerative dementia: A neuropathological study. Journal of the Neurological Sciences, 2011, 300, 63-66.	0.6	72
116	Medial temporal lobe atrophy in stroke patients: relation to pre-existing dementia. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 641-647.	1.9	71
117	Prevalence of Subcortical Vascular Lesions and Association With Executive Function in Mild Cognitive Impairment Subtypes. Stroke, 2007, 38, 2595-2597.	2.0	70
118	Contribution of <i>ATXN2</i> intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology, 2014, 83, 990-995.	1.1	70
119	Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer's disease: A review. Ageing Research Reviews, 2016, 27, 15-22.	10.9	70
120	Is the Urea Cycle Involved in Alzheimer's Disease?. Journal of Alzheimer's Disease, 2010, 21, 1013-1021.	2.6	68
121	Couples' experiences with early-onset dementia: An interpretative phenomenological analysis of dyadic dynamics. Dementia, 2016, 15, 1082-1099.	2.0	68
122	Absence of β-Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia. Archives of Neurology, 2007, 64, 583.	4.5	67
123	Aging and cerebrovascular lesions in pure and in mixed neurodegenerative and vascular dementia brains: aÂneuropathological study. Folia Neuropathologica, 2018, 56, 81-87.	1.2	67
124	Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. Neurobiology of Disease, 2008, 31, 41-45.	4.4	66
125	Cognitive Decline and Survival in Alzheimer's Disease according to Education Level. Dementia and Geriatric Cognitive Disorders, 2008, 25, 74-80.	1.5	65
126	Influence of pre-existing dementia on the risk of post-stroke epileptic seizures. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1649-1653.	1.9	63

#	Article	IF	CITATIONS
127	Systematic Analysis of Candidate Genes for Alzheimer's Disease in a French, Genome-Wide Association Study. Journal of Alzheimer's Disease, 2010, 20, 1181-1188.	2.6	63
128	Insulin-Like Growth Factor-I and Insulin-Like Growth Factor Binding Protein-3 in Alzheimer's Disease. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4673-4681.	3.6	63
129	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimer's and Dementia, 2013, 9, 406-413.	0.8	63
130	TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. Neurobiology of Aging, 2015, 36, 3116.e5-3116.e8.	3.1	63
131	<i>ABCA7</i> rare variants and Alzheimer disease risk. Neurology, 2016, 86, 2134-2137.	1.1	63
132	Frontotemporal Dementia: Its Rediscovery. European Neurology, 1997, 38, 1-6.	1.4	59
133	Disturbance of sensory filtering in dementia with Lewy bodies: comparison with Parkinson's disease dementia and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 106-108.	1.9	59
134	Early Onset Dementia. Alzheimer Disease and Associated Disorders, 2011, 25, 203-205.	1.3	58
135	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
136	17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression. Molecular Psychiatry, 2017, 22, 1119-1125.	7.9	57
137	Visit-to-Visit Blood Pressure Variability Is Associated With Cognitive Decline and Incident Dementia. Hypertension, 2020, 76, 1280-1288.	2.7	57
138	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. Journal of Neurology, 2014, 261, 144-151.	3.6	56
139	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
140	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
141	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
142	The impact of cerebral amyloid angiopathy on the occurrence of cerebrovascular lesions in demented patients with Alzheimer features: a neuropathological study. European Journal of Neurology, 2011, 18, 913-918.	3.3	54
143	PLD3 and sporadic Alzheimer's disease risk. Nature, 2015, 520, E1-E1.	27.8	54
144	Update on tauopathies. Current Opinion in Neurology, 2017, 30, 589-598.	3.6	54

9

#	Article	IF	CITATIONS
145	Association between coding variability in the LRP gene and the risk of late-onset Alzheimer's disease. Human Genetics, 1999, 104, 432-434.	3.8	53
146	Iron deposits in postâ€mortem brains of patients with neurodegenerative and cerebrovascular diseases: a semiâ€quantitative 7.0ÂT magnetic resonance imaging study. European Journal of Neurology, 2014, 21, 1026-1031.	3.3	53
147	Unmet support needs of early-onset dementia family caregivers: a mixed-design study. BMC Nursing, 2014, 13, 49.	2.5	53
148	Long-term outcome of acute and subacute myelopathies. Journal of Neurology, 2009, 256, 980-988.	3.6	52
149	Impact of the 2008–2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. Journal of Alzheimer's Disease, 2013, 34, 297-305.	2.6	51
150	Effects of the PPAR- <i>α</i> Agonist Fenofibrate on Acute and Short-Term Consequences of Brain Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 542-551.	4.3	51
151	Neurite density is reduced in the presymptomatic phase of <i>C9orf72</i> disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 387-394.	1.9	50
152	Early epileptic seizures after stroke are associated with increased risk of new-onset dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 514-516.	1.9	48
153	Added value of ¹⁸ Fâ€florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. Alzheimer's and Dementia, 2018, 14, 293-305.	0.8	48
154	Qualitative and quantitative assessment of selfâ€reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and l²â€amyloid imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 23-34.	2.4	47
155	NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. BMJ Open, 2014, 4, e006364.	1.9	47
156	Central and Peripheral Agraphia in Alzheimer's Disease: From the Case of Auguste D. to a Cognitive Neuropsychology Approach. Cortex, 2007, 43, 935-951.	2.4	46
157	Post-mortem 7.0-tesla magnetic resonance study of cortical microinfarcts in neurodegenerative diseases and vascular dementia with neuropathological correlates. Journal of the Neurological Sciences, 2014, 346, 85-89.	0.6	46
158	Medial temporal lobe atrophy in memory disorders. Journal of Neurology, 1997, 244, 175-181.	3.6	45
159	Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimer's Research and Therapy, 2017, 9, 67.	6.2	45
160	Methylenetetrahydrofolate reductase deficiency revealed by a neuropathy in a psychotic adult Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 765-766.	1.9	44
161	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimer's Research and Therapy, 2014, 6, 38.	6.2	44
162	Evidence for induction of the ornithine transcarbamylase expression in Alzheimer's disease. Molecular Psychiatry, 2009, 14, 106-116.	7.9	43

#	Article	IF	CITATIONS
163	Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. Current Alzheimer Research, 2012, 9, 902-912.	1.4	42
164	The Significance of Cortical Cerebellar Microbleeds and Microinfarcts in Neurodegenerative and Cerebrovascular Diseases. Cerebrovascular Diseases, 2015, 39, 138-143.	1.7	42
165	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimer's and Dementia, 2016, 12, 614-622.	0.8	42
166	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
167	Calculation and number processing in mild Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 1995, 17, 634-639.	1.3	41
168	White Matter Changes and Poststroke Dementia. Dementia and Geriatric Cognitive Disorders, 1998, 9, 25-29.	1.5	40
169	ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease. EBioMedicine, 2016, 9, 278-292.	6.1	40
170	First principle study on the electronic properties and Schottky contact of graphene adsorbed on MoS 2 monolayer under applied out-plane strain. Surface Science, 2018, 668, 23-28.	1.9	39
171	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
172	Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer's Disease Before 51 Years. Journal of Alzheimer's Disease, 2019, 71, 227-243.	2.6	39
173	Nonâ€Alzheimer degenerative dementias. Current Opinion in Neurology, 1998, 11, 417-427.	3.6	39
174	Diffuse form of argyrophilic grain disease: a new variant of four-repeat tauopathy different from limbic argyrophilic grain disease. Acta Neuropathologica, 2003, 106, 575-583.	7.7	38
175	Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. Journal of Clinical Psychiatry, 2016, 77, e1631-e1638.	2.2	38
176	Tacrine efficacy in Lewy body dementia. International Journal of Geriatric Psychiatry, 1998, 13, 516-519.	2.7	37
177	Association of 3'-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's disease. Journal of Medical Genetics, 2003, 40, 424-430.	3.2	37
178	The Cognitive Syndrome of Vascular Dementia. Alzheimer Disease and Associated Disorders, 1999, 13, S21-29.	1.3	36
179	Association study of the GAB2 gene with the risk of developing Alzheimer's disease. Neurobiology of Disease, 2008, 30, 103-106.	4.4	34
180	Primary and Secondary Care Consultations in Elderly Demented Individuals in France. Dementia and Geriatric Cognitive Disorders, 2008, 26, 407-415.	1.5	34

#	Article	IF	CITATIONS
181	Detection of microbleeds in postâ€mortem brains of patients with frontotemporal lobar degeneration: a 7.0â€Tesla magnetic resonance imaging study with neuropathological correlates. European Journal of Neurology, 2012, 19, 1355-1360.	3.3	34
182	Lateral Temporal Lobe: An Early Imaging Marker of the Presymptomatic GRN Disease?. Journal of Alzheimer's Disease, 2015, 47, 751-759.	2.6	34
183	A Comparative Descriptive Study of Characteristics of Early- and Late-Onset Dementia Family Caregivers. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 48-56.	1.9	33
184	Structural, Microstructural, and Metabolic Alterations in Primary Progressive Aphasia Variants. Frontiers in Neurology, 2018, 9, 766.	2.4	33
185	Creutzfeldt-Jakob disease. Neurology, 1998, 51, 962-967.	1.1	32
186	Definite Behavioral Variant of Frontotemporal Dementia with C9ORF72 Expansions Despite Positive Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2012, 32, 19-22.	2.6	32
187	A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast Cancer Research and Treatment, 2015, 152, 569-580.	2.5	32
188	The incidence of post-mortem neurodegenerative and cerebrovascular pathology in mixed dementia. Journal of the Neurological Sciences, 2016, 366, 164-166.	0.6	32
189	Coordinating Supply Chains With a General Price-Dependent Demand Function: Impacts of Channel Leadership and Information Asymmetry. IEEE Transactions on Engineering Management, 2016, 63, 390-403.	3.5	32
190	A FE65 polymorphism associated with risk of developing sporadic late-onset Alzheimer's disease but not with Al² loading in brains. Neuroscience Letters, 2000, 293, 29-32.	2.1	31
191	DAPHNE: A New Tool for the Assessment of the Behavioral Variant of Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 503-516.	1.3	31
192	Do spouse caregivers of young and older persons with dementia have different needs? A comparative study. Psychogeriatrics, 2017, 17, 282-291.	1.2	31
193	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
194	Vascular Dementia: The Role of Cerebral Infarcts. Alzheimer Disease and Associated Disorders, 1999, 13, S38-S48.	1.3	30
195	Silent infarcts in stroke patients: patient characteristics and effect on 2-year outcome. Journal of Neurology, 2001, 248, 271-278.	3.6	29
196	Memantine Therapy for Alzheimer Disease in Real-world Practice. Alzheimer Disease and Associated Disorders, 2008, 22, 125-130.	1.3	29
197	Evidence for apolipoprotein E ε4 association in early-onset Alzheimer's patients with late-onset relatives. American Journal of Medical Genetics Part A, 1995, 60, 550-553.	2.4	28
198	Explicit Memory in Frontotemporal Dementia: The Role of Medial Temporal Atrophy. Dementia and Geriatric Cognitive Disorders, 1998, 9, 99-102.	1.5	28

#	Article	IF	CITATIONS
199	Relevance of White Matter Changes to Pre- and Poststroke Dementia. Annals of the New York Academy of Sciences, 2000, 903, 466-469.	3.8	28
200	Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer's disease. Neuroscience Letters, 2004, 368, 290-292.	2.1	28
201	Evaluation of the Impact of Memantine Treatment Initiation on Psychotropics Use: A Study from the French National Health Care Database. Neuroepidemiology, 2008, 31, 193-200.	2.3	28
202	Gesture comprehension, knowledge and production in Alzheimer's disease. European Journal of Neurology, 2012, 19, 1037-1044.	3.3	28
203	Prevalence of cerebrovascular lesions in patients with Lewy body dementia: A neuropathological study. Clinical Neurology and Neurosurgery, 2013, 115, 1094-1097.	1.4	28
204	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. Journal of Alzheimer's Disease, 2016, 54, 1459-1471.	2.6	28
205	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
206	Poststroke Dementia in the Elderly. Drugs and Aging, 2005, 22, 483-493.	2.7	27
207	Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia. Neurobiology of Aging, 2012, 33, 2082-2090.	3.1	27
208	From â€~needing to know' to â€~needing not to know more': an interpretative phenomenological analysis of couples' experiences with earlyâ€onset Alzheimer's disease. Scandinavian Journal of Caring Sciences, 2016, 30, 695-703.	2.1	27
209	18F-FDG PET hypometabolism patterns reflect clinical heterogeneity in sporadic forms of early-onset Alzheimer's disease. Neurobiology of Aging, 2017, 59, 184-196.	3.1	27
210	Generation Effect in Short-Term Verbal and Visuospatial Memory: Comparisons Between Dementia of Alzheimer Type and Dementia of Frontal Lobe Type. Cortex, 1996, 32, 347-356.	2.4	26
211	Diabetes and cognitive impairment: how to evaluate the cognitive status?. Diabetes and Metabolism, 2010, 36, S100-S105.	2.9	26
212	Superficial Siderosis of the Central Nervous System: A Post-Mortem 7.0-Tesla Magnetic Resonance Imaging Study with Neuropathological Correlates. Cerebrovascular Diseases, 2013, 36, 412-417.	1.7	26
213	Emotional and Psychological Implications of Early AD Diagnosis. Medical Clinics of North America, 2013, 97, 459-475.	2.5	26
214	Antihypertensive agents in Alzheimer's disease: beyond vascular protection. Expert Review of Neurotherapeutics, 2020, 20, 175-187.	2.8	26
215	Clinical, Neuropathological, and Biochemical Characterization of the Novel Tau Mutation P332S. Journal of Alzheimer's Disease, 2012, 31, 741-749.	2.6	25
216	The <i>MAPT</i> gene is differentially methylated in the progressive supranuclear palsy brain. Movement Disorders, 2016, 31, 1883-1890.	3.9	25

#	Article	IF	CITATIONS
217	Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 485-493.	1.9	25
218	Plasma NfL levels and longitudinal change rates in <i>C9orf72</i> and <i>GRN</i> -associated diseases: from tailored references to clinical applications. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1278-1288.	1.9	25
219	Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. Alzheimer's Research and Therapy, 2021, 13, 19.	6.2	25
220	The Use of SPECT in a Multidisciplinary Memory Clinic. Dementia and Geriatric Cognitive Disorders, 1997, 8, 85-91.	1.5	24
221	Reasons that prevent the inclusion of <scp>A</scp> lzheimer's disease patients in clinical trials. British Journal of Clinical Pharmacology, 2013, 75, 1089-1097.	2.4	24
222	Modeling the Distress of Spousal Caregivers of People with Dementia. Journal of Alzheimer's Disease, 2016, 55, 703-716.	2.6	24
223	Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. Neurobiology of Aging, 2020, 91, 167.e1-167.e9.	3.1	24
224	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
225	Convulsive effects of tacrine. Lancet, The, 1996, 347, 1339-1340.	13.7	23
226	Trazodone in the treatment of behaviour in frontotemporal dementia. Human Psychopharmacology, 1999, 14, 279-281.	1.5	23
227	Neural correlates of episodic memory in the Memento cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 224-233.	3.7	23
228	Primary Progressive Aphasia Associated With <i>GRN</i> Mutations. Neurology, 2021, 97, e88-e102.	1.1	23
229	Diabetes Mellitus and Cognition. Neurology, 2021, 97, e836-e848.	1.1	23
230	Sundowning syndrome in demented patients without neuroleptic therapy. Archives of Gerontology and Geriatrics, 1996, 22, 49-54.	3.0	22
231	Laboratory investigations and treatment in frontotemporal dementia. Annals of Neurology, 2003, 54, S32-S35.	5.3	22
232	Action and noun fluency testing to distinguish between Alzheimer's disease and dementia with Lewy bodies. Journal of Clinical and Experimental Neuropsychology, 2013, 35, 259-268.	1.3	22
233	Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice. Journal of Alzheimer's Disease, 2014, 40, 857-861.	2.6	22
234	Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 1045-1054.	2.6	22

#	Article	IF	CITATIONS
235	SPECT Data in a Case of Secondary Capgras Delusion. Psychopathology, 1994, 27, 211-214.	1.5	21
236	Is There a Typical Pattern of Brain SPECT Imaging in Alzheimer's Disease?. Dementia and Geriatric Cognitive Disorders, 2001, 12, 371-378.	1.5	21
237	Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease. Human Molecular Genetics, 2008, 17, 2863-2867.	2.9	21
238	CHMP2B mutations are rare in French families with frontotemporal lobar degeneration. Journal of Neurology, 2010, 257, 2032-2036.	3.6	21
239	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. Journal of Alzheimer's Disease, 2016, 51, 905-913.	2.6	21
240	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. BMJ Open, 2016, 6, e011584.	1.9	21
241	Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD. Journal of the American Medical Directors Association, 2020, 21, 194-200.	2.5	21
242	Personality traits and frontal lobe dementia. International Journal of Geriatric Psychiatry, 1995, 10, 1047-1049.	2.7	20
243	Thrombolytic therapy for stroke in patients with preexisting cognitive impairment. Neurology, 2014, 82, 2048-2054.	1.1	20
244	Epidemiology of Vascular Dementia. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1998, 28, 134-150.	0.3	19
245	Can the Treatment of Vascular Risk Factors Slow Cognitive Decline in Alzheimer's Disease Patients?. Journal of Alzheimer's Disease, 2012, 32, 765-772.	2.6	19
246	Cerebrovascular Lesions in Patients with Frontotemporal Lobar Degeneration: A Neuropathological Study. Neurodegenerative Diseases, 2012, 9, 170-175.	1.4	19
247	Memory loss during lenalidomide treatment: a report on two cases. BMC Pharmacology & Toxicology, 2013, 14, 41.	2.4	19
248	Microbleeds in Postmortem Brains of Patients With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2013, 27, 162-167.	1.3	19
249	Animal Spotting in Alzheimer's Disease: An Eye Tracking Study of Object Categorization. Journal of Alzheimer's Disease, 2014, 39, 181-189.	2.6	19
250	Survival and early recourse to care for dementia: A population based study. Alzheimer's and Dementia, 2015, 11, 385-393.	0.8	19
251	Do spouse caregivers of persons with early- and late-onset dementia cope differently? A comparative study. Archives of Gerontology and Geriatrics, 2017, 69, 162-168.	3.0	19
252	A New Decision Tree Combining Abeta 1-42 and p-Tau Levels in Alzheimer's Diagnosis. Current Alzheimer Research, 2013, 10, 357-364.	1.4	19

#	Article	IF	CITATIONS
253	Does culture shape our understanding of others' thoughts and emotions? An investigation across 12 countries Neuropsychology, 2022, 36, 664-682.	1.3	19
254	Study of Estrogen Receptor-α and Receptor-β Gene Polymorphisms on Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 431-439.	2.6	18
255	Does pre-existing cognitive impairment no-dementia influence the outcome of patients treated by intravenous thrombolysis for cerebral ischaemia?: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1412-1414.	1.9	18
256	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. Alzheimer's Research and Therapy, 2016, 8, 27.	6.2	18
257	Multiple Simultaneous Spontaneous Intracerebral Hemorrhages: A Rare Entity. Cerebrovascular Diseases, 2016, 41, 74-79.	1.7	18
258	Influence of Lewy Pathology on Alzheimer's Disease Phenotype: AÂRetrospective Clinico-Pathological Study. Journal of Alzheimer's Disease, 2018, 63, 1317-1323.	2.6	18
259	Determination of medial temporal lobe atrophy In early Alzheimer's disease with computed tomography. Lancet, The, 1994, 343, 861-862.	13.7	17
260	Contribution of Single Photon Emission Computed Tomography to the Differential Diagnosis of Dementia in a Memory Clinic. Journal of Alzheimer's Disease, 2012, 30, 833-845.	2.6	17
261	National Observatory on the Therapeutic Management in Ambulatory Care Patients Aged 65 and Over, with Type 2 Diabetes, Chronic Pain or Atrial Fibrillation. Therapie, 2013, 68, 265-283.	1.0	17
262	Differential processing of natural scenes in posterior cortical atrophy and in Alzheimerââ,¬â"¢s disease, as measured with a saccade choice task. Frontiers in Integrative Neuroscience, 2014, 8, 60.	2.1	17
263	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open, 2019, 9, e026380.	1.9	17
264	Telling the difference between frontotemporal dementia and Alzheimer's disease. Current Opinion in Psychiatry, 2005, 18, 628-632.	6.3	16
265	Study of thyroid hormone receptor alpha gene polymorphisms on Alzheimer's disease. Neurobiology of Aging, 2011, 32, 624-630.	3.1	16
266	Topographic distribution of brain iron deposition and small cerebrovascular lesions in amyotrophic lateral sclerosis and in frontotemporal lobar degeneration: a post-mortem 7.0-tesla magnetic resonance imaging study with neuropathological correlates. Acta Neurologica Belgica, 2017, 117, 873-878.	1.1	16
267	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. BMJ Open, 2019, 9, e029663.	1.9	16
268	An acceptance, role transition, and couple dynamics-based program for caregivers: A qualitative study of the experience of spouses of persons with young-onset dementia. Dementia, 2020, 19, 2714-2731.	2.0	16
269	Topography of Cortical Microbleeds in Alzheimer's Disease with and without Cerebral Amyloid Angiopathy: A Post-Mortem 7.0-Tesla MRI Study. , 2015, 6, 437.		16
270	A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease. Neuroscience Letters, 2010, 468, 1-2.	2.1	15

#	Article	IF	CITATIONS
271	Scene Categorization in Alzheimer's Disease: A Saccadic Choice Task. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 1-12.	1.3	15
272	Does amnesia specifically predict Alzheimer's pathology? AÂneuropathological study. Neurobiology of Aging, 2020, 95, 123-130.	3.1	15
273	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiology of Disease, 2013, 54, 486-491.	4.4	14
274	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. Frontiers in Neurology, 2020, 11, 149.	2.4	14
275	Cognitive inhibition impairments in presymptomatic <i>C9orf72</i> carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 366-372.	1.9	14
276	Clinical relevance of brain atrophy subtypes categorization in memory clinics. Alzheimer's and Dementia, 2021, 17, 641-652.	0.8	14
277	Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort. Alzheimer's Research and Therapy, 2022, 14, .	6.2	14
278	No effect of the alpha 1-antichymotrypsin A allele in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 103-105.	1.9	13
279	Bilateral Temporal Glioma Presenting as a Paraneoplastic Limbic Encephalitis With Pure Cognitive Impairment. Neurologist, 2009, 15, 208-211.	0.7	13
280	Analysing time to event data in dementia prevention trials: The example of the guidage study of EGB761A®. Journal of Nutrition, Health and Aging, 2015, 19, 1009-1011.	3.3	13
281	Predicting falls in elderly patients with chronic pain and other chronic conditions. Aging Clinical and Experimental Research, 2015, 27, 653-661.	2.9	13
282	Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias. Neurology, 2018, 90, e1057-e1065.	1.1	13
283	Caring for Individuals with Early-Onset Dementia and Their Family Caregivers: The Perspective of Health Care Professionals. Advances in Alzheimer's Disease, 2014, 03, 33-43.	0.9	13
284	Absence of the amyloid precursor protein gene mutation (APP717: Val->IIe) in 85 cases of early onset Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 112-113.	1.9	12
285	Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain. European Journal of Clinical Pharmacology, 2014, 70, 1237-1242.	1.9	12
286	A Customized Intervention for Dementia Caregivers: A Quasi-Experimental Design. Journal of Aging and Health, 2019, 31, 1172-1195.	1.7	12
287	Investigating the association between cancer and the risk of dementia: Results from the Memento cohort. Alzheimer's and Dementia, 2021, 17, 1415-1421.	0.8	12
288	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12

#	Article	IF	CITATIONS
289	Dementia in stroke. Neurology, 1996, 47, 852-853.	1.1	12
290	Motor memory and the preselection effect in Huntington's and Parkinson's disease. Neuropsychologia, 1994, 32, 951-968.	1.6	11
291	Prestroke dementia in patients with atrial fibrillation. Journal of Neurology, 2005, 252, 1504-1509.	3.6	11
292	Detection of Cortical Microbleeds in Postmortem Brains of Patients with Lewy Body Dementia: A 7.0-Tesla Magnetic Resonance Imaging Study with Neuropathological Correlates. European Neurology, 2015, 74, 158-161.	1.4	11
293	Healthcare costs associated with elderly chronic pain patients in primary care. European Journal of Clinical Pharmacology, 2015, 71, 939-947.	1.9	11
294	The Topography of Cortical Microinfarcts in Neurodegenerative Diseases and in Vascular Dementia: A Postmortem 7.0-Tesla Magnetic Resonance Imaging Study. European Neurology, 2016, 76, 57-61.	1.4	11
295	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
296	Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#. Current Alzheimer Research, 2017, 14, 686-694.	1.4	11
297	Segregation analysis of Alzheimer pedigrees: Rare mendelian dominant mutation(s) explain a minority of early-onset cases. American Journal of Medical Genetics Part A, 1996, 67, 9-12.	2.4	10
298	Association between medial temporal lobe atrophy on CT and parietotemporal uptake decrease on SPECT in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 441-445.	1.9	10
299	Neuropsychiatric afflictions of modern French Presidents: Maréchal Henriâ€Philippe Pétain and Paul Deschanel. European Journal of Neurology, 1999, 6, 133-136.	3.3	10
300	Prevention of dementia: Syst-Eur trial. Lancet, The, 1999, 353, 236.	13.7	10
301	Different patterns of Mini Mental Status Examination responses in primary progressive aphasia and Alzheimer's disease. European Journal of Neurology, 2006, 13, 1124-1127.	3.3	10
302	Mild Alzheimer's disease: A «Position Paper». Journal of Nutrition, Health and Aging, 2009, 13, 503-519.	3.3	10
303	An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Experimental Neurology, 2010, 223, 432-438.	4.1	10
304	Validation of the Test Your Memory (F-TYM Test) in a French Memory Clinic Population. Clinical Neuropsychologist, 2014, 28, 994-1007.	2.3	10
305	Characteristics of the spouse caregiving experience: Comparison between early- and late-onset dementia. Aging and Mental Health, 2018, 22, 1213-1221.	2.8	10
306	Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 297.	3.4	10

#	Article	IF	CITATIONS
307	Blood Pressure Lowering With Nilvadipine in Patients With Mildâ€toâ€Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. Journal of the American Heart Association, 2019, 8, e011938.	3.7	10
308	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
309	Affective disorders related to spect patterns in alzheimer's disease: A study of emotionalism. International Journal of Geriatric Psychiatry, 1994, 9, 327-329.	2.7	9
310	The Cognitive Syndrome of Vascular Dementia: Implications for Clinical Trials. Alzheimer Disease and Associated Disorders, 1999, 13, S21-S29.	1.3	9
311	Is the ornithine transcarbamylase gene a genetic determinant of Alzheimer's disease?. Neuroscience Letters, 2009, 449, 76-80.	2.1	9
312	Unusual features of Creutzfeldt–Jakob disease followed-up in a memory clinic. Journal of Neurology, 2014, 261, 696-701.	3.6	9
313	Primary care management of non-institutionalized elderly diabetic patients: The S.AGES cohort – Baseline data. Primary Care Diabetes, 2015, 9, 267-274.	1.8	9
314	Sociolinguistic reflection on neuropsychological assessment: an insight into selected culturally adapted battery of Lebanese Arabic cognitive testing. Neurological Sciences, 2015, 36, 1813-1822.	1.9	9
315	Topographic distribution of white matter changes and lacunar infarcts in neurodegenerative and vascular dementia syndromes: A post-mortem 7.0-tesla magnetic resonance imaging study. European Stroke Journal, 2016, 1, 122-129.	5.5	9
316	Cerebrovascular Lesions in Mixed Neurodegenerative Dementia: A Neuropathological and Magnetic Resonance Study. European Neurology, 2017, 78, 1-5.	1.4	9
317	Attentional capture by incongruent object/background scenes in patients withÂAlzheimer disease. Cortex, 2018, 107, 4-12.	2.4	9
318	Role of cortical microbleeds in cognitive impairment: InÂvivo behavioral and imaging characterization of a novel murine model. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1015-1025.	4.3	9
319	Primary progressive aphasias associated with C9orf72 expansions: Another side of the story. Cortex, 2021, 145, 145-159.	2.4	9
320	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
321	Comparison of secondary vascular prevention in practice after cerebral ischemia and coronary heart disease. Journal of Neurology, 2004, 251, 529-536.	3.6	8
322	Editorial Comment—Not All Hypertensive Subjects Have Similar Risks for White Matter Lesions: Influence of Genetic Factors. Stroke, 2004, 35, 1061-1062.	2.0	8
323	CP measurement in quantum teleportation of neutral mesons. European Physical Journal C, 2008, 55, 477-482.	3.9	8
324	Factors influencing the age at onset in familial frontotemporal lobar dementia. Neurology: Genetics, 2017, 3, e203.	1.9	8

#	Article	IF	CITATIONS
325	Frequency and topography of small cerebrovascular lesions in vascular and in mixed dementia: a post-mortem 7-tesla magnetic resonance imaging study with neuropathological correlates. Folia Neuropathologica, 2017, 1, 31-37.	1.2	8
326	Frontotemporal dementia is the leading cause of "true―Aâ^'/T+ profiles defined with Aβ _{42/40} ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169.	2.4	8
327	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, .	1.1	8
328	Characteristics of familial aggregation in early-onset Alzheimer's disease: Evidence of subgroups. American Journal of Medical Genetics Part A, 1995, 60, 221-227.	2.4	7
329	Rapid categorization of faces and objects in a patient with impaired object recognition. Neurocase, 2010, 16, 157-168.	0.6	7
330	Therapeutic management in ambulatory elderly patients with atrial fibrillation: The S.AGES cohort. Journal of Nutrition, Health and Aging, 2015, 19, 219-227.	3.3	7
331	Optimization of brain perfusion image quality by cortical surface-based projection of arterial spin labeling maps in early-onset Alzheimer's disease patients. European Radiology, 2015, 25, 2479-2484.	4.5	7
332	Cardiovascular Drugs and Metformin Drug Dosage According to Renal Function in Nonâ€Institutionalized Elderly Patients. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 468-473.	2.5	7
333	Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients With Type 2 Diabetes: A Cohort Study. Canadian Journal of Diabetes, 2018, 42, 365-371.e2.	0.8	7
334	Subjective cognitive and nonâ€cognitive complaints and brain MRI biomarkers in the MEMENTO cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12051.	2.4	7
335	Twentyâ€year trends in patient referrals throughout the creation and development of a regional memory clinic network. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12048.	3.7	7
336	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	1.9	7
337	<i>SLITRK2</i> , an X-linked modifier of the age at onset in <i>C9orf72</i> frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811.	7.6	7
338	Longitudinal Analysis of Brain-Predicted Age in Amnestic and Non-amnestic Sporadic Early-Onset Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 729635.	3.4	7
339	New behavioural variant FTD criteria and clinical practice. Revue Neurologique, 2013, 169, 799-805.	1.5	6
340	Original article Prevalence of small cerebral bleeds in patients with progressive supranuclear palsy: aÂneuropathological study with 7.0-Tesla magnetic resonance imaging correlates. Folia Neuropathologica, 2014, 4, 421-427.	1.2	6
341	The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 324-333.	6.4	6
342	Meningitis Caused BySalmonella Enteritidis in an Adult. Acta Clinica Belgica, 1992, 47, 215-216.	1.2	5

#	Article	IF	CITATIONS
343	Relevance of the Evaluation Criteria Used in Clinical Trials for Alzheimer's Disease. Therapie, 2009, 64, 145-148.	1.0	5
344	Neuronal substrate of cognitive impairment in post-stroke dementia. Brain, 2014, 137, 2404-2405.	7.6	5
345	Association between Cardiovascular Drugs and Chronic Kidney Disease in Nonâ€Institutionalized Elderly Patients. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 137-143.	2.5	5
346	Differences in cortical perfusion detected by arterial spin labeling in nonamnestic and amnestic subtypes of early-onset Alzheimer's disease. Journal of Neuroradiology, 2020, 47, 284-291.	1.1	5
347	The Clinical Value of the Faux Pas Test for Diagnosing Behavioral-Variant Frontotemporal Dementia. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 62-65.	2.3	5
348	Sedative Load in Community-Dwelling Older Adults with Mild–Moderate Alzheimer's Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls. Drugs and Aging, 2020, 37, 829-837.	2.7	5
349	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	1.4	5
350	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.1	5
351	Allelic association at the D14S43 locus in early onset Alzheimer's disease. American Journal of Medical Genetics Part A, 1995, 60, 91-93.	2.4	4
352	Influence of Dementia on Antithrombotic Therapy Prescribed before Stroke in Patients with Atrial Fibrillation. Cerebrovascular Diseases, 2006, 21, 401-407.	1.7	4
353	Influence of cognitive impairment on the management of ischaemic stroke. Revue Neurologique, 2014, 170, 177-186.	1.5	4
354	Hyperinsulinemic hypoglycemia without insulinoma: Think of activating glucokinase mutation. Presse Medicale, 2018, 47, 595-597.	1.9	4
355	Sex Differences in the Occurrence of Major Clinical Events in Elderly People with Type 2 Diabetes Mellitus Followed up in the General Practice. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 311-318.	1.2	4
356	Three-year changes of cortical 18F-FDG in amnestic vs. non-amnestic sporadic early-onset Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 304-318.	6.4	4
357	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
358	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	6.2	4
359	Poststroke dementia. , 2001, , 273-284.		3
360	Patients characteristics with cholinesterase inhibitor resistant hallucinations in dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1415-1416.	1.9	3

#	Article	IF	CITATIONS
361	Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics. Journal of Alzheimer's Disease, 2015, 49, 1075-1083.	2.6	3
362	Young onset demented patients in French cognitive-behavioral specialized units. Psychologie & Neuropsychiatrie Du Vieillissement, 2016, 14, 194-200.	0.2	3
363	P1-291: Hypometabolism Patterns Using FDC-PET in Typical and Atypical Sporadic Forms of Early-Onset Alzheimer's Disease. , 2016, 12, P532-P532.		3
364	A multimodal, longitudinal study of cognitive heterogeneity in earlyâ€onset Alzheimer's disease. European Journal of Neurology, 2021, 28, 3990-3998.	3.3	3
365	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	3.1	3
366	The topography of cortical microbleeds in frontotemporal lobar degeneration: a post-mortem 7.0-tesla magnetic resonance study. Folia Neuropathologica, 2016, 2, 149-155.	1.2	3
367	Telemedicine in French Memory Clinics During the COVID-19 Pandemic. Journal of Alzheimer's Disease, 2022, 86, 525-530.	2.6	3
368	Interoception and social cognition in chronic low back pain: a common inference disturbance? An exploratory study. Pain Management, 2022, 12, 471-485.	1.5	3
369	Declaration of San Antonio, Texas. Neuroepidemiology, 2007, 28, 191-192.	2.3	2
370	Graph wavelet applied to human brain connectivity. , 2009, , .		2
371	Adenosine Receptors and Alzheimer's Disease. , 2013, , 385-407.		2
372	Using EQ·PET to reduce reconstruction-dependent variations in [18F]FDG-PET brain imaging. Physics in Medicine and Biology, 2019, 64, 175002.	3.0	2
373	Development and Validation of a Scale to Assess Caregiver Management Behaviors in Response to the Decreased Engagement of People with Dementia in Daily Activities. Clinical Gerontologist, 2022, 45, 514-524.	2.2	2
374	Association of Amyotrophic Lateral Sclerosis and Alzheimer's Disease: New Entity or Coincidence? A Case Series. Journal of Alzheimer's Disease, 2021, 84, 1439-1446.	2.6	2
375	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
376	Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease. Age and Ageing, 1998, 27, 654-654.	1.6	1
377	Biomarkers for the Early Stages of Clinical Development in Alzheimer's Disease. Therapie, 2010, 65, 285-290.	1.0	1
378	Cerebral amyloid angiopathy revealed by rapidly progressing leptomeningeal lesions. Journal of Neurology, 2014, 261, 1432-1435.	3.6	1

#	Article	IF	CITATIONS
379	Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology, 2016, 87, 1523-1523.	1.1	1
380	Lobar intracerebral haematomas: Neuropathological and 7.0-tesla magnetic resonance imaging evaluation. Journal of the Neurological Sciences, 2016, 369, 121-125.	0.6	1
381	Relationship between achieved personalized glycaemic targets and monitoring of clinical events in elderly diabetic patients. Diabetes and Metabolism, 2017, 43, 59-68.	2.9	1
382	[P1–240]: CLINICAL IMPACT OF CEREBROSPINAL FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P336.	0.8	1
383	[P1–251]: CLINICAL PROFILE OF PATIENTS WITH NORMAL CSF Aβ42 AND Aβ42/Aβ40 RATIO, YET ABNORMAL 181Pâ€TAU: A SNAP STORY. Alzheimer's and Dementia, 2017, 13, P343.	CSF 0.8	1
384	Les Démences Frontotemporales. , 2008, , 123-135.		1
385	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
386	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
387	Clinical and Imaging Characteristics of Vascular Dementia in a Memory Clinic. , 0, , 219-228.		Ο
388	Chapter 8 Dementia. Blue Books of Practical Neurology, 2001, 25, 147-172.	0.1	0
389	P1-048 Natural history of primary progressive aphasia. Neurobiology of Aging, 2004, 25, S108.	3.1	Ο
390	Prevalence of risk factors of prion-related disease according to the French circular 138 (DGS/DH/5C/DHOS/E2/2001/138) among patients referred for gastrointestinal endoscopy. Gastroenterologie Clinique Et Biologique, 2005, 29, 664-666.	0.9	0
391	Poststroke dementia. , 0, , 245-254.		Ο
392	Treatment of patients with post-stroke dementia. , 0, , 423-431.		0
393	P3-277: DO GERIATRIC AND NEUROLOGICAL MEMORY CLINICS DIFFER? A LONGITUDINAL STUDY OVER 16 YEARS OF A NETWORK OF MEMORY CLINICS IN FRANCE. , 2014, 10, P733-P733.		Ο
394	THE ROLE OF THE MEMORY RESOURCES AND RESEARCH CENTER IS ENHANCED BY A 16-YEAR NETWORK ORGANIZATION OF MEMORY CLINICS IN THE NORTH OF FRANCE. , 2014, 10, P223-P223.		0
395	ICâ€Pâ€149: Qualiâ€Quantitative Assessment of Selfâ€Reported Cognitive Difficulties in Nonâ€Demented Elders: Relationships With Medical Help Seeking, Cognition and Neuroimaging Biomarkers. Alzheimer's and Dementia, 2016, 12, P110.	0.8	0
396	P1-394: Prevalence and Characteristics of Patients with Alzheimer's Disease Eligible for a Disease Modifying Drug (Panacea). , 2016, 12, P584-P584.		0

#	Article	IF	CITATIONS
397	ICâ€Pâ€113: Hypometabolism Patterns Using FDGâ€PET in Typical and Atypical Sporadic Forms of Earlyâ€Onset Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P85.	0.8	0
398	P2â€343: Qualiâ€Quantitative Assessment of Selfâ€Reported Cognitive Difficulties in Nonâ€Demented Elders: Relationships with Medical Help Seeking, Cognition and Neuroimaging Biomarkers. Alzheimer's and Dementia, 2016, 12, P774.	0.8	0
399	P1â€058: Nilvad: An Investigator Driven Phase III Multi Centre European Clinical Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P424.	0.8	0
400	P3â€305: Exploring the Anatomical Substrate of Episodic Memory: the Structural Mri Correlates of the Free and Cued Selective Reminding Test in ihe Memento Cohort. Alzheimer's and Dementia, 2016, 12, P958.	0.8	0
401	[P3–364]: ACCELERATED SUBCORTICAL ATROPHY DURING AGING IN PRESYMPTOMATIC CARRIERS OF C9ORF7 MUTATION. Alzheimer's and Dementia, 2017, 13, P1096.	⁷² 0.8	0
402	[ICâ€Pâ€126]: ACCELERATED SUBCORTICAL ATROPHY DURING AGING IN PRESYMPTOMATIC CARRIERS OF C9OR MUTATION. Alzheimer's and Dementia, 2017, 13, P95.	F72 0.8	0
403	Frontotemporal Dementia. Neuropsychiatric Symptoms of Neurological Disease, 2017, , 279-302.	0.3	0
404	[P4–251]: PATTERNS OF CORTICAL NEUROANATOMICAL ABNORMALITITES IN TYPICAL AND ATYPICAL SPORADIC FORMS OF EARLYâ€ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1375.	0.8	0
405	[ICâ€Pâ€107]: PATTERNS OF CORTICAL NEUROANATOMICAL ABNORMALITITES IN TYPICAL AND ATYPICAL SPORA FORMS OF EARLYâ€ONSET ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P82.	NDIC	0
406	De la maladie de Pick aux démences fronto-temporales. Bulletin De L'Academie Nationale De Medecine, 2012, 196, 431-443.	0.0	0
407	Abstract P2-13-10: Prospective randomized and multicentric evaluation of cognition in menopausal breast cancer patients receiving adjuvant hormonotherapy: a phase III study (Preliminary results). , 2012, , .		0
408	Lewy Body Influence on Tacrine Efficacy. Advances in Behavioral Biology, 1998, , 477-480.	0.2	0
409	Post-Mortem 7.0-Tesla Magnetic Resonance Imaging of the Hippocampus in Progressive Supranuclear Palsy with and without Cerebral Amyloid Angiopathy. NeuroSci, 2020, 1, 115-120.	1.2	О